Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Maine .
Press releases published on May 15, 2025
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
GlobeNewswire
·
May 15, 2025
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May …
Christophe Girardier, CEO of Glimpact, to Speak at Three Public Events During hub.brussels’ Impact Mission 2025 in New York
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Christophe Girardier, CEO of Glimpact the first platform for analyzing the overall systemic environmental impact of products and organizations, will speak at three public events hosted by hub.brussels during …
CORA Group Announces the Appointment of Beth McCoy to President of CORA Loyalty
GlobeNewswire
·
May 15, 2025
WARMINSTER, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- CORA Group (“CORA”), an operating portfolio of Jonas Software, a subsidiary of Constellation Software Inc., announced today that Beth McCoy was promoted to President of CORA Loyalty, reporting to Denis …
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
GlobeNewswire
·
May 15, 2025
Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1 below 1 (TPS <1%), who represent an area …
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
—Reported Positive 48-Week Data from SPRING Trial—Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis— —Aligned with FDA on Pathway to …
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025 OPGx-BEST1 on …
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an …
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 15, 2025
FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company …
Polpharma Group fordert dringende Maßnahmen zum Schutz eines frühzeitigen und gerechten Zugangs zu Medikamenten für europäische Patienten
GlobeNewswire
·
May 15, 2025
WARSCHAU, Polen, May 15, 2025 (GLOBE NEWSWIRE) -- Die Polpharma Group, ein führendes Pharmaunternehmen, fordert die Europäische Union nachdrücklich auf, entschlossene Maßnahmen zu ergreifen, um die Arzneimittelreform abzuschließen und die Kapazitäten …
Polpharma Group plaide en faveur d’une action urgente en vue de garantir aux patients européens un accès équitable et précoce aux médicaments
GlobeNewswire
·
May 15, 2025
VARSOVIE, Pologne, 15 mai 2025 (GLOBE NEWSWIRE) -- Polpharma Group, acteur pharmaceutique de première importance, enjoint l’Union européenne à arrêter des mesures décisives pour finaliser la réforme du secteur pharmaceutique et renforcer la capacité du …
Intchains Group Limited to Participate in the “Virtual Digital Assets Seminar” Presented by Benchmark Company on Tuesday, May 20th at 9:45 a.m. EDT
GlobeNewswire
·
May 15, 2025
SINGAPORE, May 15, 2025 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies, and …
Launch a stable income contract through the BlockchainCloudMining platform to quickly realize the diversification of cryptocurrency assets and double the wealth
GlobeNewswire
·
May 15, 2025
Miami, FL, May 15, 2025 (GLOBE NEWSWIRE) -- In 2025, the cryptocurrency market is experiencing rapid development. With the steady rise in the price of Bitcoin (BTC) and the continuous innovation of major digital currencies such as Ethereum (ETH), investor …
Echo Launches Worldwide and Starts Exclusive Public Sale for the ECHO Token
GlobeNewswire
·
May 15, 2025
Douglas, Isle of Man, May 15, 2025 (GLOBE NEWSWIRE) -- Echo, a revolutionary centralized crypto exchange, officially launched worldwide on May 15, marking a historical event for the digital asset trading landscape. On the same day, the platform started …
ZenaTech Reports Nearly Double Revenue Year-Over-Year for the First Quarter of 2025
GlobeNewswire
·
May 15, 2025
VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum …
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
May 15, 2025
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic …
Avicanna Reports Q1 2025 Results and First Profitable Quarter
GlobeNewswire
·
May 15, 2025
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Digi Power X Reports 65% Increase in Q1 2025 Revenue Over Prior Quarter With no Long-Term Debt
GlobeNewswire
·
May 15, 2025
MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), a vertically integrated power infrastructure company focused on developing cutting-edge data centers for high-performance computing, is …
LeddarTech gibt Einführung von LeddarSim bekannt: Der nächste Quantensprung in der realistischen Simulation von Fahrerassistenzsystemen (Realistic Advanced Driver Assistance System, ADAS) und autonomem Fahren (Autonomous Driving, AD)
GlobeNewswire
·
May 15, 2025
QUEBEC CITY, Kanada, May 15, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. („LeddarTech“) (Nasdaq: LDTC), ein auf KI-Technologie spezialisiertes Softwareunternehmen, das für seine Innovationen im Bereich fortschrittlicher Fahrerassistenzsysteme (ADAS) …
レダーテック (LeddarTech)、LeddarSimのリリースを発表：現実的な先進運転支援システム (ADAS) と自動走行 (AD) シミュレーションにおける次の飛躍
GlobeNewswire
·
May 15, 2025
カナダ・ケベックシティ発, May 15, 2025 (GLOBE NEWSWIRE) -- 先進運転支援システム (ADAS) と自動運転 (AD) の革新で知られる、AIを活用したソフトウエア企業であるレダーテック・ホールディングス (LeddarTech® Holdings Inc.) (「レダーテック」) (NASDAQ: LDTC) は、バーチャルテストと実世界での展開のギャップを縮めることを目的に構築された次世代シミュレーションプラットフォーム、LeddarSim™のリリースを発表した。 …